共 42 条
- [1] Genovese MC(2008)Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study Arthritis Rheum 58 2968-2980
- [2] McKay JD(2010)Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions Mod Rheumatol 20 222-232
- [3] Nasonov EL(2009)Blockade of interleukin 6 signaling induces marked neutropenia in patients with rheumatoid arthritis J Rheumatol 36 459-460
- [4] Nishimoto N(2014)A14: neutropenia with tocilizumab treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis Arthritis Rheumatol 66 S23-S24
- [5] Ito K(2014)A45: neutropenia with tocilizumab treatment is not associated with increased infection risk in patients with polyarticular-course juvenile idiopathic arthritis Arthritis Rheumatol 66 S67-S68
- [6] Takagi N(2007)Antitumor necrosis factor-induced neutropenia: a case report with double positive rechallenges Clin Rheumatol 26 1527-1529
- [7] Nakamura I(2008)Three significant cases of neutropenia with etanercept Rheumatology (Oxford) 47 376-377
- [8] Omata Y(2009)Adalimumab-induced neutropenia in a patient with rheumatoid arthritis Joint Bone Spine 76 312-313
- [9] Naito M(2006)Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis Ann Rheum Dis 65 1678-1679
- [10] De Benedetti F(2012)Re-challenge with Etanercept in patients with Etanercept-induced Neutropenia Clin Rheumatol 31 151-155